Soligenix opens enrollment in Phase 2a trial of SGX302 for mild-to-moderate psoriasis

SOLIGENIX, INC.

Phase 2a study (HPN-PSR-01) initiating enrollment of up to 42 patients with mild-to-moderate psoriasis.
Part A open-label (5-10 patients) followed by Part B double-blind 1:1 active vs. placebo for 18 weeks treatment plus 4-week follow-up.
SGX302 (synthetic hypericin) activated by visible light; efficacy endpoints include lesion clearance and quality of life.
Psoriasis affects ~7.5M people in U.S. and 60-125M worldwide; Soligenix estimates >$1B global market for SGX302.
SGX302 also under NDA review for cutaneous T-cell lymphoma (Phase 3 FLASH study).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.